Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HEALTHCARE (NY: XLV )

144.03 +1.15 (+0.80%)
Official Closing Price Updated: 8:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about HEALTHCARE

< Previous 1 2 Next >
Defensive Sectors: Shielding Your Portfolio in Volatile Times
Defensive sectors like consumer staples, healthcare, real estate, and utilities tend to perform well during market downturns and heightened volatility. 
Via MarketBeat
Topics Economy Stocks
Exposures COVID-19 Economy Interest Rates
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property Product Safety
MarketBeat Week in Review – 7/29 - 8/2
The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
The healthcare sector, represented by the XLV ETF, has seen a resurgence, breaking out of a multi-year consolidation phase and surging almost 3% in July. 
Via MarketBeat
Topics ETFs
Pharma Leader Beats on Earnings, But Shares Fall
Novartis released its Q2 financial results. It beat expectations on EPS and revenue. However, shares fell, possibly due to bad news on one upcoming drug. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
The Top 3 Sectors Poised For Growth This Summer
Communications, technology, and healthcare are the three hottest sectors for growth, but not all stocks will rise with the tides. 
Via MarketBeat
Topics ETFs
Hims & Hers Health Stock Could Become a Wealth Compounder
Hims & Hers stock could give investors the best of both stability and double-digit upside through EPS projections and price targets, especially after 1Q24 
Via MarketBeat
Topics Economy
Exposures Economy
CVS Stock is Nearing a 52-Week Low, Better Buy Than Walgreens?
CVS stock is making its way above Walgreens as a potential watchlist addition. Fundamentals and price targets see the stock making a comeback this year. 
Via MarketBeat
Citi’s Results Say This About The Stock Market
Investors now have an inside look at what one of Wall Street's biggest names is doing with its money. Corporations and clients all see new highs in stocks 
Via MarketBeat
Topics Economy
Exposures Interest Rates
3 High Dividend Socks to Replace Lower Savings Yields Ahead
Three stocks stand out as the most attractive dividend propositions, particularly now that savings yields may drop as a result of the Fed's rate cuts 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
bluebird bio Stock Signals Potential to be a Multi-bagger
Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could do 
Via MarketBeat
Topics Economy
Exposures Economy
bluebird bio stock is ripe for a 400% institutional short squeeze
Bluebird Bio stock could be on the verge of a 400% pop on earnings, management has set the writing on the wall for institutional buying to trickle in 
Via MarketBeat
Topics Economy
Exposures Interest Rates
S&P 500 rockets to new highs as earnings beat estimates
The S&P 500 hits new highs as 10 of the 11 S&P sectors report positive Q4 earnings surprises. The tech and energy sectors are among the earnings leaders. 
Via MarketBeat
Topics ETFs Earnings Stocks
Exposures Financial US Equities
Can financial, healthcare, energy stocks rise as rates stay high?
Sectors including financials, healthcare, utilities and energy outperform as interest rates remain high, but some of those industries face challenges in 2024. 
Via MarketBeat
Markets suddenly price Eli Lilly stock for a breakout on earnings
The healthcare sector could see a sudden inflow of investment dollars, and Eli Lilly quickly becomes a favorite name in the space as markets and analysts bid up 
Via MarketBeat
Topics Bonds Economy
Exposures Debt Markets Interest Rates
Pfizer’s earnings growth trade at a deep discount, suddenly a buy
The healthcare sector is set to attract a new inflow of investment dollars, as seen in business activity and employment. Pfizer is the clear sector favorite 
Via MarketBeat
Topics Economy
Exposures Economy
5 top healthcare stocks for earnings growth in 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed. 
Via MarketBeat
Are CVS store closures prescription for better financial health?
CVS plans to close dozens of Target pharmacies starting in February. Amid retail pharmacy challenges, CVS is shifting toward the managed-care industry. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
UnitedHealth's rising premiums could cushion stubborn inflation
The healthcare sector is one of the prime suspects to attract safety-seeking investors in the coming market shift. Within it, THIS stock can prove a winner 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
AstraZeneca: Rebound in 2024 with double-digit earnings growth
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition 
Via MarketBeat
Exposures COVID-19
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges. 
Via MarketBeat
Topics ETFs
Are defensive sectors ready to outshine growth in 2024?
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead. 
Via MarketBeat
Align Technology: Protected by more factors than any other stock
Jobs are flowing to the healthcare space, and investment dollars are finding a home in stocks like Align Technology, even the CEO thought it to be the best 
Via MarketBeat
Pfizer's chaotic year wraps up with plunging stock, grim guidance
Pfizer's tumultuous 2023 included a 41.84% stock plunge as revenue from Covid drugs fell. Disappointing 2024 guidance resulted in analysts slashing targets. 
Via MarketBeat
Exposures COVID-19
Mega merger in the works? Humana, Cigna explore big deal
Humana and Cigna are exploring a merger, aiming to conclude the deal before year-end, creating a healthcare giant with a potential market value of $137 billion. 
Via MarketBeat
These are the top sectors for blue chip growth in 2024
The sector results will be mixed in 2024 but the Health Care, Communications and Technology sectors (and some of their stocks) will post robust gains. 
Via MarketBeat
Topics Economy Intellectual Property
Exposures COVID-19 Intellectual Property Interest Rates
J&J, Gilead, BMS: A look at undervalued dividend payers
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown 
Via MarketBeat
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
J&J stock down as business unit mulls talc-related bankruptcy
Johnson & Johnson stock fell in the past week as talc-related lawsuits weigh on a subsidiary, which is mulling bankruptcy to mitigate payouts and settlements. 
Via MarketBeat
Topics Bankruptcy Lawsuit
Exposures Financial Legal
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.